Treatment developments for metastatic castration-resistant prostate cancer
Art & Science Previous     Next

Treatment developments for metastatic castration-resistant prostate cancer

Louise Causer Clinical nurse specialist radionuclide therapy/radiation protection, Royal Marsden NHS Foundation Trust, Sutton, Surrey

Louise Causer discusses how bone-targeted therapy using radium-223 can be beneficial to men with the disease

Radium-223 (Ra-223) dichloride is the first bone-targeted therapy for men with metastatic castration-resistant prostate cancer (mCRPC) with the ability to improve quality of life and overall survival, and the additional advantage of a good safety profile. Ra-223 is administered as an intravenous injection and since the radioactivity is low, it can be given on an outpatient basis with appropriate radiation protection procedures.

As Ra-223 has the potential to play a significant role in management of men with mCRPC, it is important to establish appropriate protocols and procedures to accommodate its use in standard clinical practice.

Cancer Nursing Practice. 14, 2,31-37. doi: 10.7748/cnp.14.2.31.e1171

Correspondence

Louise.Causer@rmh.nhs.uk

Peer review

This article has been subject to double blind peer review

Conflict of interest

Bamboo Medical Communications Ltd provided medical writing services to the author, which were funded by Bayer Plc. These services included drafting and subsequent revision of the manuscript under the guidance of the author, who had final responsibility for the manuscript content and made the decision to submit the manuscript for publication.

Received: 19 December 2014

Accepted: 02 February 2015